Last reviewed · How we verify

NCT06291818

Self-Adhering Magnetic Device to Treat Corneal Exposure

Recruiting now NA Last updated 13 May 2024
What this trial tests

NA trial testing temporary magnetic system for tarsorrhaphy (MST) in Paralytic Lagophthalmos in 25 participants. Currently enrolling.

Timeline
17 April 2024
Primary endpoint
1 December 2024
1 April 2025

Quick facts

Lead sponsorUniversity of Illinois at Chicago
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment25
Start date17 April 2024
Primary completion1 December 2024
Estimated completion1 April 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Illinois at Chicago

Who can join

Adults 18 to 80, any sex, with Paralytic Lagophthalmos or Corneal Exposure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Paralytic lagophthalmos can be difficult to treat and manage. It has a host of causes and effects, one of which (for the latter) is exposure keratopathy. Untreated, this can lead to corneal ulceration, inflammation, and potentially blindness. Despite a variety of attempts at treating this complex condition, none have satisfactorily reduced complications ranging from ease of use to aesthetics. With improvement in magnetic technology, however, that may change. Barmettler et al (2014) have demonstrated preliminary success of externally affixed magnets in closing both model and patient eyelids. As such, we hypothesize that magnetic devices can be used to treat corneal exposure by controlling eyelid position.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Paralytic Lagophthalmos

Currently open trials in the same condition.

Other University of Illinois at Chicago trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06291818.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing